207 related articles for article (PubMed ID: 27298405)
1. Management of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer.
Rusthoven CG; Doebele RC
J Clin Oncol; 2016 Aug; 34(24):2814-9. PubMed ID: 27298405
[TBL] [Abstract][Full Text] [Related]
2. Concurrent Chemotherapy and Radiation Therapy for Inoperable Locally Advanced Non-Small-Cell Lung Cancer.
Rosenzweig KE; Gomez JE
J Clin Oncol; 2017 Jan; 35(1):6-10. PubMed ID: 27870565
[TBL] [Abstract][Full Text] [Related]
3. Optimizing Treatment Risk and Benefit for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Right Treatment for the Right Patient.
Presley CJ; Gross CP; Lilenbaum RC
J Clin Oncol; 2016 May; 34(13):1438-42. PubMed ID: 27001591
[TBL] [Abstract][Full Text] [Related]
4. Decision Making in a Data-Poor Environment: Management of Brain Metastases From Testicular and Extragonadal Germ Cell Tumors.
Gilligan T
J Clin Oncol; 2016 Feb; 34(4):303-6. PubMed ID: 26668343
[TBL] [Abstract][Full Text] [Related]
5. Advanced adenocarcinoma of the lung: comparison of CT characteristics of patients with anaplastic lymphoma kinase gene rearrangement and those with epidermal growth factor receptor mutation.
Choi CM; Kim MY; Hwang HJ; Lee JB; Kim WS
Radiology; 2015 Apr; 275(1):272-9. PubMed ID: 25575117
[TBL] [Abstract][Full Text] [Related]
6. Different histopathology but the same clonality: ALK rearrangement in a patient with metastatic non-small-cell lung cancer.
Zhao J; Zhou J; Chen Z; Wang B; Zhang X; Zhou J; Ding W
Int J Clin Exp Pathol; 2015; 8(3):3344-8. PubMed ID: 26045865
[TBL] [Abstract][Full Text] [Related]
7. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment.
Proietti A; Alì G; Pelliccioni S; Lupi C; Sensi E; Boldrini L; Servadio A; Chella A; Ribechini A; Cappuzzo F; Miccoli M; Fontanini G
Cancer Cytopathol; 2014 Jun; 122(6):445-53. PubMed ID: 24648382
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary Infiltrates in a Patient With Advanced Melanoma.
Powell CA
J Clin Oncol; 2017 Mar; 35(7):705-708. PubMed ID: 28029320
[TBL] [Abstract][Full Text] [Related]
9. Improving Treatment Options for Brain Metastases From ALK-Positive Non-Small-Cell Lung Cancer.
Wardak Z; Choy H
J Clin Oncol; 2016 Dec; 34(34):4064-4065. PubMed ID: 27863198
[No Abstract] [Full Text] [Related]
10. [Treatment of Patients with ALK-positive Non-small Cell Lung Cancer
and Brain Metastases].
Lv J; Zhang Q; Qin N; Yang X; Zhang X; Wu Y; Li X; Zhang H; Wang J; Zhang S
Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):519-24. PubMed ID: 27561801
[TBL] [Abstract][Full Text] [Related]
11. Adding bevacizumab to chemotherapy effectively control radioresistant brain metastases in ALK-positive lung adenocarcinoma.
Su YL; Rau KM
J Thorac Oncol; 2015 Apr; 10(4):e21-2. PubMed ID: 25789840
[No Abstract] [Full Text] [Related]
12. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
Dacic S; Villaruz LC; Abberbock S; Mahaffey A; Incharoen P; Nikiforova MN
Oncotarget; 2016 Dec; 7(50):82943-82952. PubMed ID: 27769042
[TBL] [Abstract][Full Text] [Related]
13. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
Kimura H; Nakajima T; Takeuchi K; Soda M; Mano H; Iizasa T; Matsui Y; Yoshino M; Shingyoji M; Itakura M; Itami M; Ikebe D; Yokoi S; Kageyama H; Ohira M; Nakagawara A
Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253
[TBL] [Abstract][Full Text] [Related]
14. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
15. Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene.
Pelosi G; Gasparini P; Cavazza A; Rossi G; Graziano P; Barbareschi M; Perrone F; Barberis M; Takagi M; Kunimura T; Yamada T; Nakatani Y; Pastorino U; Scanagatta P; Sozzi G; Garassino M; De Braud F; Papotti M
Lung Cancer; 2012 Sep; 77(3):507-14. PubMed ID: 22705117
[TBL] [Abstract][Full Text] [Related]
16. Molecular alterations in non-small cell lung carcinomas of the young.
VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z
Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236
[TBL] [Abstract][Full Text] [Related]
17. Discordance between anaplastic lymphoma kinase status in primary non-small-cell lung cancers and their corresponding metastases.
Kim H; Xu X; Yoo SB; Sun PL; Jin Y; Paik JH; Choe G; Jheon S; Lee CT; Chung JH
Histopathology; 2013 Jan; 62(2):305-14. PubMed ID: 23020707
[TBL] [Abstract][Full Text] [Related]
18. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G
Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803
[TBL] [Abstract][Full Text] [Related]
19. The value of ultrasound-guided biopsy of fluorodeoxy-glucose positron emission tomography (FDG-PET)-positive supraclavicular lymph nodes in patients with suspected lung cancer.
Werner L; Keller FA; Bhure U; Roos JE; Tornquist K; Del Sol Pèrez-Lago M; Gautschi O; Strobel K
BMC Med Imaging; 2017 Jul; 17(1):41. PubMed ID: 28693444
[TBL] [Abstract][Full Text] [Related]
20. Duration of Anti-Programmed Death-1 Therapy in Advanced Melanoma: How Much of a Good Thing Is Enough?
Khushalani NI
J Clin Oncol; 2018 Jun; 36(17):1649-1653. PubMed ID: 29389234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
